Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Tumour-associated macrophages (TAMs) largely express an alternatively activated (or M2) phenotype, which entails immunosuppressive and tumour-promoting capabilities. Reprogramming TAMs towards a classically activated (M1) phenotype may thwart tumour-associated immunosuppression and unleash anti-tumour immunity. Here we show that conditional deletion of the microRNA (miRNA)-processing enzyme DICER in macrophages prompts M1-like TAM programming, characterized by hyperactive IFN-γ/STAT1 signalling. This rewiring abated the immunosuppressive capacity of TAMs and fostered the recruitment of activated cytotoxic T lymphocytes (CTLs) to the tumours. CTL-derived IFN-γ exacerbated M1 polarization of Dicer1-deficient TAMs and inhibited tumour growth. Remarkably, DICER deficiency in TAMs negated the anti-tumoral effects of macrophage depletion by anti-CSF1R antibodies, and enabled complete tumour eradication by PD1 checkpoint blockade or CD40 agonistic antibodies. Finally, genetic rescue of Let-7 miRNA activity in Dicer1-deficient TAMs partly restored their M2-like phenotype and decreased tumour-infiltrating CTLs. These findings suggest that DICER/Let-7 activity opposes IFN-γ-induced, immunostimulatory M1-like TAM activation, with potential therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Macrophages have been shown to be plastic [334,335,336].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [334]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Cited by
Items 101–200 of 260
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
Hu, J., Xiao, Q., Dong, M., Guo, D., Wu, X., & Wang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.593219 · Cited by 55
Zheng, W., Qian, C., Tang, Y., Yang, C., Zhou, Y., Shen, P., Chen, W., Yu, S., Wei, Z., Wang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035323 · Cited by 53
“It has been shown that hyperactive IFN-g/ STAT1 signaling cascade propels the reprograming of TAMs to M1-like profile, contributing to vascular remodeling and subsequent tumor destruction (83, 131).”
BackgroundMujal, A. M., Combes, A. J., Rao, A. A., Binnewies, M., Samad, B., Tsui, J., Boissonnas, A., Pollack, J. L., Argüello, R. J., Meng, M. V., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0588 · Cited by 58
Singh, M. P., Sethuraman, S. N., Ritchey, J. W., Fiering, S., Guha, C., Malayer, J. R., & Ranjan, A. (2019) · International Journal of Hyperthermia · doi:10.1080/02656736.2019.1663280 · Cited by 50
“In particular, tumor-associated macrophages (TAMs) of M1 origin suppress T-cell exhaustion [52,53].”
BackgroundPeriostin Limits Tumor Response to VEGFA Inhibition
Keklikoglou, I., Kadioglu, E., Bissinger, S., Langlois, B., Bellotti, A., Orend, G., Ries, C. H., & Palma, M. D. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.035 · Cited by 47
Self-citationMicroRNAs: At the Interface of Metabolic Pathways and Inflammatory Responses by Macrophages
Nelson, M. C., & O’Connell, R. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01797 · Cited by 47
Drulă, R., Pardini, B., Fu, X., Santos, M. C. D. L., Jurj, A. M., Pang, L., El‐Daly, S. M., Fabris, L., Knutsen, E., Dragomir, M. P., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122053120 · Cited by 43
Rubio, C., Munera-Maravilla, E., Lodewijk, I., Suárez-Cabrera, C., Karaivanova, V., Ruiz-Palomares, R., Paramio, J. M., & Dueñas, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1952-y · Cited by 46
Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
Dong, Y., Wan, Z., Gao, X., Yang, G., & Liu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609762 · Cited by 47
“inhibition of DICER, a key enzyme for microRNA synthesis in macrophages switches the subtype accompanied by tumor regression and infiltration of effective immune cells (115).”
BackgroundIFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young
Gauthier, T., & Chen, W. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0132 · Cited by 51
Davidov, V., Jensen, G. L., Mai, S., Chen, S., & Pan, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01842 · Cited by 47
Key questions about the checkpoint blockade-are microRNAs an answer?
Dragomir, M. P., Chen, B., Fu, X., & George, A. C. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0006 · Cited by 42
Ishii, H., Vodnala, S. K., Achyut, B. R., So, J. Y., Hollander, M. C., Greten, T. F., Lal, A., & Li, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-05023-9 · Cited by 44
MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages
Chen, C., Liu, J., & Luo, Y. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900452 · Cited by 41
Lepland, A., Asciutto, E. K., Malfanti, A., Simón‐Gracia, L., Sidorenko, V., Vicent, M. J., Teesalu, T., & Scodeller, P. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00226 · Cited by 42
Li, T., Zhai, X., Jiang, J., Song, X., Han, W., Ma, J., Xie, L., Li, C., Chen, H., & Jiang, L. (2016) · Brain Research · doi:10.1016/j.brainres.2016.12.006 · Cited by 46
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 41
“2019) and reprogramming TAMs from M2- to M1-like phenotypes (Baer et al. 2016).”
BackgroundSu, P., Li, O., Ke, K., Jiang, Z., Wu, J., Wang, Y., Mou, Y., & Jin, W. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5648 · Cited by 47
“The inhibition of DICER, an RNase‑III enzyme that regulates the maturation of miRNA, reprograms TAMs into an anti‑tumor phenotype and promotes tumor regression (7,198).”
BackgroundMyeloid effector cells in cancer
Schol, P. J., van Elsas, M. J., Middelburg, J., Twilhaar, M. K. N., van Hall, T., van der Sluis, T. C., & van der Burg, S. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.002 · Cited by 41
Ding, Y., Yang, J., Wei, H., Wang, J., Huang, S., Yang, S., Guo, Y., Li, B., & Shuai, X. (2023) · Small · doi:10.1002/smll.202301420 · Cited by 42
MicroRNAs in Macrophages: Regulators of Activation and Function
Sprenkle, N. T., Serezani, C. H., & Pua, H. H. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200467 · Cited by 41
Elebyary, O., Barbour, A., Fine, N. A., Tenenbaum, H. C., & Glogauer, M. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2020.584705 · Cited by 41
“Additionally, these cells have potent anti-tumor capabilities and treatments that can induce tumor-associated macrophages to adopt an M1 phenotype hold potential therapeutic promise [76].”
BackgroundBeyond the M‐ CSF receptor – novel therapeutic targets in tumor‐associated macrophages
Bonelli, S., Geeraerts, X., Bolli, E., Keirsse, J., Kiss, M., Antunes, A. R. P., Damme, H. V., Vlaminck, K. D., Movahedi, K., Laoui, D., et al. (2017) · FEBS Journal · doi:10.1111/febs.14202 · Cited by 42
Self-citationDiamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
Clappaert, E. J., Murgaski, A., Damme, H. V., Kiss, M., & Laoui, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02250 · Cited by 41
“The TAM’s phenotype switch was associated with enhanced tumor infiltration by cytotoxic T-cells (CTLs) and IFN-γ production, MC38 tumor inhibition and, importantly, increased tumor responsiveness to PD1 checkpoint blockade (69).”
BackgroundSelf-citationKemmner, S., Bachmann, Q., Steiger, S., Lorenz, G., Honarpisheh, M. M., Foresto‐Neto, O., Wang, S., Carbajo-Lozoya, J., Alt, V., Schulte, C., et al. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00004.2018 · Cited by 40
“Depletion of Dicer1, a miRNA-processing RNase III enzyme, leads to the absence of miRNA, which in macrophages increases the upregulation of, for example, IP-10 and CXCL9 and skews macrophages toward a classically activated phenotype (3).”
BackgroundPerdas, E., Stawski, R. S., Kaczka, K., & Zubrzycka, M. (2020) · Diagnostics · doi:10.3390/diagnostics10030130 · Cited by 38
“The M2 phenotype is associated with increased angiogenesis and tumor aggressiveness, while TAMs with M1 phenotype show proinflammatory activity and better prognosis [35].”
BackgroundMicroRNAs: As Critical Regulators of Tumor- Associated Macrophages
Chatterjee, B., Saha, P., Bose, S., Shukla, D., Chatterjee, N., Kumar, S., Tripathi, P. P., & Srivastava, A. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197117 · Cited by 40
“let-7d-5p Promote M2-like phenotype [16]”
INT-HA induces M2-like macrophage differentiation of human monocytes via TLR4-miR-935 pathway
Zhang, B., Du, Y., He, Y., Liu, Y., Zhang, G., Yang, C., & Gao, F. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2261-6 · Cited by 39
Galliverti, G., Tichet, M., Domingos‐Pereira, S., Hauert, S., Nardelli‐Haefliger, D., Swartz, M. A., Hanahan, D., & Wullschleger, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0166 · Cited by 37
“The following antibodies were used for immunofluorescence staining: CD8 (clone 53-6.7, eBioscience), keratin 14 (clone poly19053, BioLegend), ICOS (clone 7E.17G9, BD Biosciences), F4/80-PE (clone BM8, eBioscience), CD11c-FITC (clone N418, BioLegend), MRC1-Alexa Fluor 647 (clone C068C2, BioLegend), and PD-L1-PE (MIH5,…”
BackgroundInfluentialMultifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
Yang, L., Li, F., Cao, Y., Liu, Q., Jing, G., Niu, J., Sun, F., Qian, Y., Wang, S., & Li, A. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01073-2 · Cited by 36
“The quantity and function of various immune cells in the TIME were evaluated.”
BackgroundInfluentialAhmad, A. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.09.001 · Cited by 35
Chen, P., Zhang, X., Venosa, A., Lee, I.-H.-O., Myers, D. R., Holloway, J., Prud'homme, R., Gao, D.-Y., Székely, Z., Laskin, J., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030243 · Cited by 33
Defining and targeting tumor-associated macrophages in malignant mesothelioma
Wu, L., Kohno, M., Murakami, J., Zia, A., Allen, J., Yun, H., Chan, M., Baciu, C., Liu, M., Serre‐Beinier, V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210836120 · Cited by 42
“Considering the importance of selective macrophage depletion to mediate the most benefit in cancer therapy, we next specifically focused on depleting M2-like macrophages by using mice with myeloid-specific inactivation of the Dicer1 gene (D) (30).”
BackgroundYuan, M., Zhu, Z., Mao, W., Wang, H., Qian, H., Wu, J., Guo, X., & Xu, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683502 · Cited by 33
“Hyperactive IFN-g/STAT1 signaling promotes M1-like TAM reprogramming, leading to vascular remodeling and consequent tumor eradication (49, 50).”
BackgroundTumor-Associated Neutrophils Show Phenotypic and Functional Divergence in Human Lung Cancer
Saha, S., & Biswas, S. K. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.016 · Cited by 33
“Phenotypic heterogeneity is well-known for tumor-associated macrophages (TAMs), Cancer Ce wherein co-existence of inflammatory and immunosuppressive TAM subsets has been noted in several tumor types (Baer et al., 2016; Biswas and Mantovani, 2010; Movahedi et al., 2010).”
BackgroundTumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy
Huang, Y., Fan, H., & Ti, H. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100902 · Cited by 54
Fu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 39
“Activation of macrophages via CD40, characteristic of the M1 phenotype, leads to increased release of pro-inflammatory cytokines and upregulated expression of antigen-presenting molecules such as MHC-II ( Baer et al., 2016 ).”
BackgroundGlial polarization in neurological diseases: Molecular mechanisms and therapeutic opportunities
Liu, Y., Wu, L., Peng, W., & Mao, X. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102638 · Cited by 36
Wang, H., Xu, S., Li, D., & Xie, Z. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c05593 · Cited by 32
Macrophage MicroRNAs as Therapeutic Targets for Atherosclerosis, Metabolic Syndrome, and Cancer
Wei, Y., Zhu, M., & Schober, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061756 · Cited by 33
Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
Guerra, E., Pietro, R. D., Basile, M., Trerotola, M., & Alberti, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010405 · Cited by 32
“Broader approaches to TAM reprogramming include inhibition of DICER, a pivotal enzyme for microRNA synthesis [125], and inhibitors of histone deacetylase [126].”
MethodTang, R., Luo, G., Zhao, L., Huang, L., Qin, Y., Xu, X., Su, Y., & Yan, Q. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.03.051 · Cited by 29
Selective targeting of tumor associated macrophages in different tumor models
Kakoschky, B., Pleli, T., Schmithals, C., Zeuzem, S., Brüne, B., Vogl, T. J., Korf, H., Weigert, A., & Piiper, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193015 · Cited by 31
Dong, Y., Zhang, S., Gao, X., Yin, D., Wang, T., Li, Z., Wan, Z., Wei, M., Luo, Y., Yang, G., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.008 · Cited by 39
“For example, studies have shown that antiCD47 antibodies [27,28], toll-like receptor agonist [29], anti-CD40 antibodies [30], histone deacetylase inhibitors [31], anti-MARCO antibody therapy [32], PI3Kγ inhibitors [33] and inhibition of related miRNAs [34] are intensively studied strategies for TAMs repolarization [16…”
BackgroundAsciutto, E. K., Kopanchuk, S., Lepland, A., Simón‐Gracia, L., Alemán, C., Teesalu, T., & Scodeller, P. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b11876 · Cited by 27
Luo, X., Hu, R., Zheng, Y., Liu, S., & Zhou, Z. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13074 · Cited by 32
Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Ho, R. L. Y., & Ho, I. A. W. (2021) · Cancers · doi:10.3390/cancers13153686 · Cited by 34
“While TH1-derived IFN-γ may trigger TAMs to elicit STAT-1-induced C-X-C motif ligand (CXCL)-9- and 10-mediated angiostatic responses, TH2derived IL-4 promotes M2-like TAM activation by STAT-6 to enhance angiogenesis [82,83].”
BackgroundMortara, L., Benest, A. V., Bates, D. O., & Noonan, D. M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.009 · Cited by 30
Lewandowska-Sabat, A. M., Hansen, S., Solberg, T. R., Østerås, O., Heringstad, B., Boysen, P., & Olsaker, I. (2018) · BMC Genomics · doi:10.1186/s12864-018-4591-3 · Cited by 30
Self-citationLiu, T., Han, T., Liu, C., Ge, C., Jiang, X., Liu, Y., Kong, F., Su, X., Shi, J., Su, W., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126323 · Cited by 27
Jia, W., Luo, S., Lai, G., Li, S., Huo, S., Li, M., & Zeng, X. Z. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03318-x · Cited by 30
Tan, S., Wang, Z., Li, N., Guo, X., Zhang, Y., Ma, H., Peng, X., Zhao, Y., Li, C., Gao, L., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01202-4 · Cited by 28
Kim, S. H., Saeidi, S., Zhong, X., Gwak, S.-Y., Muna, I. A., Park, S., Kim, S. H., Na, H., Joe, Y., Chung, H., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.08.006 · Cited by 28
“Reprogramming TAMs toward an immunestimulatory phenotype enhances the activity of immune checkpoint inhibitors [12,14,49].”
BackgroundZhang, X., Jiang, M., Niu, W., Xu, B., Zhang, C., Yang, M., Hu, S., & Niu, C. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf019 · Cited by 30
“34–36 Thus, we examined the expression of key proteins in the above-mentioned pathways in mGDE-OE-circPrkd3 or circPrkd3 overexpressed treated M2-like BMDMs, and found that phosphorylation of P65 and STAT1 were significantly increased by mGDE-OE-circPrkd3 or overexpressed circPrkd3.”
The Unfolded Protein Response at the Tumor-Immune Interface
Zanetti, M., Su, X., Dosset, M., & Carter, H. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.823157 · Cited by 25
miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review
García‐Giménez, J. L., Saadi, W., Ortega, Á., Lahoz, A., Suay, G., Carretero, J., Pereda, J., Fatmi, A., Pallardó, F. V., & Mena, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031737 · Cited by 27
“…immunosuppressive and tumor-promoting activity), suppressing interferon (IFN)- γ -induced and immunostimulatory macrophage programming in cancer [50], and a luciferase reporter assay has pro-inflammatory and tumoricidal activity of “M1” macrophage tumor-associated macrophage (TAM) phenotypes…”
BackgroundMethodConnecting the dots in the associations between diet, obesity, cancer, and microRNAs
Otsuka, K., Nishiyama, H., Kuriki, D., Kawada, N., & Ochiya, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.001 · Cited by 30
de Cauwer, A., Mariotte, A., Sibilia, J., Bahram, S., & Georgel, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01647 · Cited by 26
Lorestani, P., Dashti, M., Nejati, N., Habibi, M. A., Askari, M., Robat-Jazi, B., Ahmadpour, S., & Tavakolpour, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01256-x · Cited by 27
“Additionally, the inhibition of DICER in TAMs was found to enhance the response to immunostimulatory antibodies, suggesting a potential therapeutic target (benefit) [128].”
BackgroundYan, Y., Lu, J., Luo, H., Wang, Z., Xu, K., Wang, L., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1667464 · Cited by 29
Li, S., Zhao, S., Guo, Y., Yang, Y., Huang, J., Wang, J., Lu, S., Wang, B., Chai, C., Xu, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.864046 · Cited by 27
“IFN-g secreted by Th1 cells stimulates the activity of M1 tumor-associated macrophages, which could inhibit tumor growth (104, 105).”
BackgroundHarnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy
Park, S., & Kim, I. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.018 · Cited by 24
Fan, S., Chen, P., & Li, S. (2021) · BioMed Research International · doi:10.1155/2021/6692544 · Cited by 22
“MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate translation or degradation of mRNA by binding to the 3′-UTR of their target mRNAs [5, 6].”
BackgroundKou, Y., Sun, Q., Zhu, R., Lin, Z., Li, Z., Xu, H., Feng, X., & Liu, Y. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154559 · Cited by 23
The role of intestinal macrophage polarization in colitis-associated colon cancer
Deng, Y., Jia, X., Liu, L., He, Q., & Liu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1537631 · Cited by 31
MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis
Fodor, A., Lazăr, A.-L., Buchman, C., Tiperciuc, B., Orasan, O. H., & Cozma, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126337 · Cited by 22
“CTL-derived IFN-γ amplified M1 polarization of DICER1-deficient TAMs and inhibited tumor growth [11].”
Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer
Bao, L., Li, Y., Hu, X., Gong, Y., Chen, J., Huang, P. C., Tan, Z., Ge, M., & Pan, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112102 · Cited by 25
Tumor evolution selectively inactivates the core microRNA machinery for immune evasion
Song, T., Long, M., Zhao, H., Zou, M.-W., Fan, H., Liu, Y., Geng, C., Song, M., Liu, Y.-F., Chen, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27331-3 · Cited by 21
Subverted macrophages in the triple-negative breast cancer ecosystem
Shang, L., Zhong, Y., Yao, Y., Liu, C., Wang, L., Zhang, W., Liu, J., Wang, X., & Sun, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115414 · Cited by 23
Elchaninov, A. V., Nikitina, M., Vishnyakova, P., Lokhonina, А. V., Макаров, А. В., Sukhikh, G. T., & Fatkhudinov, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111516 · Cited by 23
Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing
Zins, K., & Abraham, D. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_17 · Cited by 24
Macrophage-Associated Disorders: Pathophysiology, Treatment Challenges, and Possible Solutions
Yadav, K., Pradhan, M., Singh, D., & Singh, M. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_4 · Cited by 24
Regulatory mechanism of macrophage polarization based on Hippo pathway
Liu, Y., An, Y., Li, G., & Wang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1279591 · Cited by 21
Majid, U., Bergsland, C. H., Sveen, A., Bruun, J., Eilertsen, I. A., Bækkevold, E. S., Nesbakken, A., Yaqub, S., Jahnsen, F. L., & Lothe, R. A. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00926-w · Cited by 21
“IFN-γ activated TAMs may thus attack and phagocytose malignant cells and provide anti-tumor activity through their capacity to stimulate T cells and produce chemokines that attract T cells [13, 14, 36].”
Pramanik, S., Harini Devi, M., Chakrabarty, S., Paylar, B., Pradhan, A., Thaker, M., Ayyadhury, S., Manavalan, A., Olsson, P., Pramanik, G., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105834 · Cited by 20
MicroRNAs in oncology: a translational perspective in the era of AI
Jurj, A. M., Dragomir, M. P., Li, Z., & Calin, G. A. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01114-x · Cited by 29
Impaired interferon-γ signaling promotes the development of silicosis
Peng, Z., Duan, M., Tang, Y., Wu, J., Zhao, K., Zhong, Y., He, Z., Meng, J., Chen, F., Xiao, X., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104647 · Cited by 18
“Activating IFN-g signaling increases direct antimicrobial and antitumor activity and promotes antigen presentation (Baer et al., 2016; Kammertoens et al., 2017; Karki et al., 2021; Kerner et al., 2020).”
BackgroundLiu, L., Gao, J., Xing, X., Jiang, M., Liu, Q., Wang, S., & Luo, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02564-2 · Cited by 18
“attenuating the tumor suppressive effects of IFN‐γ IFN-γ stimulates macrophages to secrete cytokines, which recruit CTLs [25, 26].”
BackgroundJairath, N. K., Farha, M. W., Srinivasan, S., Jairath, R., Green, M. D., Dess, R. T., Jackson, W., Weiner, A. B., Schaeffer, E. M., Zhao, S. G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061973 · Cited by 18
Elchaninov, A. V., Lokhonina, А. V., Nikitina, M., Vishnyakova, P., Макаров, А. В., Arutyunyan, I. V., Poltavets, A. S., Kananykhina, E. Y., Kovalchuk, S. I., Karpulevich, E., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8120627 · Cited by 19
“However, a number of studies show that let-7 family miRNAs, such as let-7b/c/d/e, contributed to the formation of an anti-inflammatory (alternative) macrophage phenotype [40,41].”
BackgroundTumor Cells and the Extracellular Matrix Dictate the Pro-Tumoral Profile of Macrophages in CRC
Coletta, S., Lonardi, S., Sensi, F., D’Angelo, E., Fassan, M., Pucciarelli, S., Valzelli, A., Biccari, A., Vermi, W., Bella, C. D., et al. (2021) · Cancers · doi:10.3390/cancers13205199 · Cited by 21
“Moreover, the increased expression of let-7i-5p in TAMs induces an antiinflammatory pro-tumoral profile [55].”
BackgroundKhan, A. N. H., Emmons, T. R., Magner, W. J., Alqassim, E., Singel, K. L., Ricciuti, J., Eng, K. H., Odunsi, K. O., Tomasi, T. B., Lee, K. P., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03156-x · Cited by 18
Qu, D., Qin, Y., Liu, Y., Liu, T., Liu, C., Han, T., Chen, Y., Ma, C., & Li, X. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c06949 · Cited by 16
Sun, L. N., Cheng, X., Zhi, Z., Liu, Y., Chen, L., Shen, T., Zhou, Q. Y., Liu, Y. H., Gan, W. J., Wang, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18218 · Cited by 17
“For instance, the miRNA Let-7 has been implicated in macrophage activation and anti-tumour immunity [12] .”
BackgroundYi, L., Chen, L., Guo, X., Lu, T., Wang, H., Ji, X., Zhang, J., Ren, Y., Pan, P., Kinghorn, A. D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01509 · Cited by 16
The metabolic fate of iron-based magnetic nanomaterials and their impact on macrophage function
Huang, Y., Cai, X., Yan, L., Zhang, M., Sheng, J., & Gu, N. (2025) · Magnetic Medicine · doi:10.1016/j.magmed.2025.100002 · Cited by 15
Role of microRNA 146a on the healing of cornea alkali burn treated with mesenchymal stem cells
Luo, X., Li, J., Yin, L., Pan, J., Zhang, Y., & Jiang, Z. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9328 · Cited by 15
“CD45 and IFN-γ have been demonstrated to be inflammation‑associated cytokines (26,27).”
Wu, L., Dell’Anno, I., Lapidot, M., Sekido, Y., Chan, M.-L., Kohno, M., Serre‐Beinier, V., Felley‐Bosco, E., & de Perrot, M. E. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.034 · Cited by 15
Mice with pre-existing tumors are vulnerable to postoperative cognitive dysfunction
Wu, T., Wang, X., Zhang, R., Jiao, Y., Yu, W., Su, D., Zhao, Y., & Tian, J. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146650 · Cited by 14
Trajectories of macrophage ontogeny and reprogramming in cancer
Duval, F., Lourenço, J., Hicham, M., Boivin, G., Guichard, A., Wyser-Rmili, C., Fournier, N., Mansouri, N., & de Palma, M. (2025) · iScience · doi:10.1016/j.isci.2025.112498 · Cited by 15
“11 We also used an orthotopic model of Kras G12D ; Tp53 null non-small cell lung cancer (NSCLC).”
InfluentialAssessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML
Jian-xin, S., Dian, Z.-J., Wen, Y., Mei, F., Li, R.-W., & Sa, Y.-L. (2016) · BioMed Research International · doi:10.1155/2016/8086398 · Cited by 13
Dicer up-regulation by inhibition of specific proteolysis in differentiating monocytic cells
Basavarajappa, D. K., Uebbing, S., Kreiß, M., Lukic, A., Suess, B., Steinhilber, D., Samuelsson, B. O., & Rådmark, O. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916249117 · Cited by 14
“This is in line with the finding that conditional deletion of Dicer in mouse TAMs could reprogram the macrophages into an antitumor mode (M1-like phenotype), allowing an enhanced immunotherapy response and inhibition of tumor progression (47).”
ResultRewiring macrophages for anti-tumour immunity
Lee, Y., & Biswas, S. K. (2016) · Nature Cell Biology · doi:10.1038/ncb3384 · Cited by 11
Chen, S., Wei, H., Zhao, W., Jiang, W., Ning, R., Zhou, S., Tan, L., Wang, H., Su, C., He, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059995 · Cited by 13
Applications of machine learning in tumor-associated macrophages
Li, Z., Yu, Q., Zhu, Q., Yang, X., Li, Z., & Fu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985863 · Cited by 10
The Dog as a Model to Study the Tumor Microenvironment
Carvalho, M. I., Raposo, T. P., Silva-Carvalho, R., Pires, I. C. R., Prada, J., Gregório, H., & QUEIROGA, F. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_7 · Cited by 13
Zhong, S., Ye, X., Liu, H., Ma, X., Chen, X., Zhao, L., Huang, G., Huang, L., Zhao, Y., & Qiao, Y. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109432 · Cited by 9
Deep inside of gastric signet-ring cell carcinoma
Roncati, L., Manenti, A., Barbolini, G., & Maiorana, A. (2018) · Neoplasma · doi:10.4149/neo_2018_170404n246 · Cited by 9
Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma
Liang, H., Xu, M., Xiong, Z., Hu, K., Yang, J., Cao, M., Zhong, Z., Yao, Z., Deng, M., & Liu, B. (2021) · Aging · doi:10.18632/aging.202606 · Cited by 9
Xia, S., Chen, W., Xu, Z., Gao, Y., Chen, J., Ding, N., Zhang, Y., Zhou, T., Zhou, X., Liu, X., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03518-4 · Cited by 12
“Besides, based on the genetic Dicer1 deletion method, Let-7-5p is a positive regulator of M2 polarization in TAMs [11].”
Metadata
- Authors
- Baer, C., Squadrito, M. L., Laoui, D., Thompson, D., Hansen, S. K., Kiialainen, A., Hoves, S., Ries, C. H., Ooi, C.-H., & De Palma, M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- F. Hoffmann-La Roche AG (CH)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Squadrito, Mario Leonardo
- ORCID
- Venue
- Nature Cell Biology
- Published
- 2016-06-13
- Volume
- 18
- Issue
- 7
- Pages
- 790-802
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2436603111
- Cited by
- 259
- References
- 71
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 24 · 2023: 15 · 2022: 37 · 2021: 36 · 2020: 35 · 2019: 26 · 2018: 32 · 2017: 20 · 2016: 8
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- tumour-associated macrophages, microRNA processing, Dicer, let-7 microRNA, M1 macrophage polarization, M2 macrophage phenotype, antitumor immunity, cytotoxic T lymphocytes, anti-PD-1 therapy, CSF1R blockade, macrophage depletion, tumor immunosuppression
- MeSH terms
- Animals, Cells, Cultured, Humans, Interferon-gamma, Macrophage Activation, Macrophages, Neoplasms, MicroRNAs, Ribonuclease III, Mice, DEAD-box RNA Helicases, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.